Lumexa Imaging (NASDAQ:LMRI) Trading 5.7% Higher - Time to Buy?

Key Points

• Shares rose 5.7% intraday to $10.28 (high $10.47) on Wednesday, with volume about 33% below the recent average.
• Analyst sentiment is bullish but mixed: Raymond James upgraded to a Strong Buy with a $23 target while Barclays trimmed its target to $15; the consensus rating is Strong Buy with an average target of $19.
• Lumexa missed EPS at ($0.66) vs. $0.05 expected but reported a huge revenue beat of $1.02 billion vs. $262.7 million estimated, and several institutions including Goldman Sachs and Seven Grand Managers initiated positions.

Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI - Get Free Report) shares traded up 5.7% during trading on Wednesday . The company traded as high as $10.47 and last traded at $10.28. 474,970 shares changed hands during mid-day trading, a decline of 33% from the average session volume of 708,839 shares. The stock had previously closed at $9.73.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Raymond James Financial upgraded Lumexa Imaging from an "outperform" rating to a "strong-buy" rating and set a $23.00 price objective on the stock in a research report on Monday, February 9th. Barclays decreased their price objective on Lumexa Imaging from $23.00 to $15.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 14th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Strong Buy" and an average target price of $19.00.

Lumexa Imaging Stock Up 5.7%

The company has a 50-day simple moving average of $11.16.

Lumexa Imaging (NASDAQ:LMRI - Get Free Report) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.71). The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $262.72 million. Equities analysts forecast that Lumexa Imaging Holdings, Inc. will post 0.34 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in LMRI. Assetmark Inc. bought a new position in shares of Lumexa Imaging in the 4th quarter worth $36,000. Geode Capital Management LLC bought a new position in shares of Lumexa Imaging in the 4th quarter worth $1,548,000. Seven Grand Managers LLC bought a new position in shares of Lumexa Imaging in the 4th quarter worth $11,942,000. Goldman Sachs Group Inc. bought a new position in shares of Lumexa Imaging in the 4th quarter worth $18,870,000. Finally, TD Asset Management Inc bought a new position in shares of Lumexa Imaging in the 4th quarter worth $1,264,000.

Lumexa Imaging Company Profile

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.